The recently proposed TCET rule appears to be too stringent to significantly hasten the Medicare coverage process for device makers.
While overpayments may not be your fault, they expose your lab to the risk of liability under the Affordable Care Act.
What do lab professionals need to do to ensure sufficient documentation for billing clinical laboratory and pathology services?
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
The proposed PFS rule also includes other changes that will affect physician, lab, and other reimbursements in 2024 and beyond.